title: A strategy to improve the success rate of CNS drug development: TAK-063, a novel PDE10A inhibitor, as a case study.
authors.forename: Haruhide
authors.initials: H
authors.lastname: Kimura
mesh_terms: D000818:Animals; D002491:Central Nervous System Agents / Q000737:chemistry / Q000494:pharmacology*; D015195:Drug Design; D004791:Enzyme Inhibitors / Q000494:pharmacology*; D006801:Humans; D010727:Phosphoric Diester Hydrolases / Q000378:metabolism*; D011720:Pyrazoles / Q000737:chemistry / Q000494:pharmacology*; D011724:Pyridazines / Q000737:chemistry / Q000494:pharmacology*; D015398:Signal Transduction / Q000187:drug effects
chemical_list: C000594749:1-(2-fluoro-4-(1H-pyrazol-1-yl)phenyl)-5-methoxy-3-(1-phenyl-1H-pyrazol-5-yl)pyridazin-4(1H)-one; D002491:Central Nervous System Agents; D004791:Enzyme Inhibitors; D011720:Pyrazoles; D011724:Pyridazines; C119843:PDE10A protein, human; D010727:Phosphoric Diester Hydrolases